Metformin as a repurposed therapy in advanced non-small cell lung cancer (NSCLC): results of a phase II trial

Conclusion Adding metformin to chemotherapy for advanced NSCLC was safe but did not significantly improve clinical outcomes compared to historical phase III controls. These results are limited by the small sample size; larger trials are needed.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research